1-3 of 3
Susan Lerner, M.S., RHIA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long Term Outcome Following Treatment Failure of FCR Chemoimmunotherapy as Initial Therapy for Chronic Lymphocytic Leukemia.

Michael J. Keating, M.B., B.S., William G. Wierda, M.D., Ph.D, Constantine S. Tam, M.B., B.S., Alice Lynn, Susan O'Brien, M.D., Susan Lerner, M.S., RHIA, Hagop M. Kantarjian, M.D.
Journal: Blood
Blood (2009) 114 (22): 2381.
https://doi.org/10.1182/blood.V114.22.2381.2381
Published: 2009
Journal Articles

Pretreatment Factors Associated with Second Malignancies Occuring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL).

Nicolas Batty, MD, Xavier C. Badoux, MBBS, Michael Keating, MD, E. Lin, Susan Lerner, M.S., RHIA, Susan O'Brien, Alessandra Ferrajoli, MD., Tapan Kadia, MD, Jan A. Burger, MD, PhD, Stefan Faderl, MD, William G. Wierda, M.D., Ph.D
Journal: Blood
Blood (2009) 114 (22): 3448.
https://doi.org/10.1182/blood.V114.22.3448.3448
Published: 2009
Journal Articles

Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia.

Sameer A Parikh, MD, Michael Keating, MD, Susan O'Brien, Alessandra Ferrajoli, Stefan Faderl, MD, Charles Koller, MD, Zeev Estrov, Susan Lerner, M.S., RHIA, William G. Wierda, M.D., Ph.D
Journal: Blood
Blood (2009) 114 (22): 208.
https://doi.org/10.1182/blood.V114.22.208.208
Published: 2009